| (Values in U.S. Thousands) | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 |
| Sales | 183,800 | 157,800 | 150,400 | 136,900 | 120,800 |
| Sales Growth | +16.48% | +4.92% | +9.86% | +13.33% | +8.34% |
| Net Income | 166,000 | -28,800 | -119,200 | 155,900 | 108,300 |
| Net Income Growth | +676.39% | +75.84% | -176.46% | +43.95% | +37.26% |
Assura Plc (AGR.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Assura PLC is a healthcare facility REIT. The company operates one segment that develops, owns, and manages primary-care properties. All the company's revenue is generated in the United Kingdom. Assura seeks properties that are characterized by a secure and predictable income stream with an underpinning of inflation linkage. The company considers merger and acquisition investment to be a component of its operational growth strategy. It engages in relationship-building with general practitioners to secure investment opportunities.
Fiscal Year End Date: 03/31